Global Biologics Safety Testing Industry Forecast (2024-2035)
The biologics safety testing sector is poised for significant advancement, with its global valuation projected to reach USD 13.2 Billion by 2035, up from USD 4.5 Billion in 2024. This reflects a robust compound annual growth rate (CAGR) of 11.5% throughout the forecast period. The expansion is fueled by the growing adoption of biologics in treating chronic diseases, rising investment in research and development (R&D), and stringent regulatory requirements for biologics quality assurance.
Segmental Insights
By Offering
The biologics safety testing domain is categorized into Services, Consumables, and Instruments:
Services dominate the segment, driven by outsourcing trends among biopharmaceutical companies. These include:
Sterility Testing
Mycoplasma Testing
Endotoxin Testing
Bioburden Testing
Virus Safety Testing
Other specialized testing protocols
Consumables, especially reagents and kits, are in high demand due to frequent usage and the need for replenishment in ongoing testing processes.
Instruments are crucial for mechanizing and scaling testing procedures, with innovations increasing their utility across small and large-scale laboratories.
By Application
Vaccines & Therapeutics represent a significant portion of the testing ecosystem, with increased emphasis post-COVID-19.
Cellular & Gene Therapy is witnessing accelerated growth due to rising FDA approvals and complex biologic entities that demand rigorous safety checks.
Blood & Blood-based Therapy continues to expand due to the rise in transfusion procedures and blood-derived medicinal products.
Other Applications include tissue engineering and regenerative medicine.
By End-User
Pharmaceutical & Biopharmaceutical Companies form the largest customer base, emphasizing regulatory compliance and patient safety.
Research Institutions contribute to the demand through clinical studies, trials, and the development of experimental therapies.
Other End Users, such as contract research organizations (CROs), also contribute meaningfully to industry dynamics.
Regional Analysis
The North American region dominates the biologics safety testing domain, primarily due to the presence of major pharmaceutical players, sophisticated infrastructure, and a strong regulatory framework led by the FDA.
Europe follows closely, with countries like Germany, France, and the UK showcasing substantial biotech R&D funding and government support.
Asia-Pacific is emerging as the fastest-growing region, with heightened investment in biologics manufacturing and a rising number of contract research and manufacturing organizations (CROs/CMOs) in China, India, and South Korea.
Key Industry Participants
The biologics safety testing sector is characterized by the presence of both global giants and specialized biotech firms. Leading entities include:
Abcam Limited
Thermo Fisher Scientific, Inc.
Eurofins Scientific
Merck KGaA
Lonza
Charles River Laboratories
Samsung Biologics
BIOMÉRIEUX
Sartorius AG
SGS Société Générale de Surveillance SA
Wuxi AppTec
Invetech
PathogenDx
Boehringer Ingelheim International GmbH
Microtrac Retsch GmbH
These companies are focused on strategic collaborations, product innovation, and geographic expansion to strengthen their positions in this thriving space.
Full Report Access – Prophecy Market Insights
Industry Trends and Opportunities
Rising prevalence of chronic and infectious diseases drives the need for safe biologics.
Outsourcing of safety testing services to specialized CROs is increasing, offering cost-efficiency and compliance benefits.
Stringent regulatory frameworks imposed by bodies such as FDA, EMA, and ICH are promoting advanced testing practices.
The advancement of cell and gene therapies calls for more robust and tailored safety testing protocols.
Post Your Ad Here
Comments